Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee
- PMID: 22395188
- DOI: 10.1097/MPG.0b013e318252a13f
Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adolescents in the United States, and most probably also in the rest of the industrialized world.As the prevalence of NAFLD in childhood increases with the worldwide obesity epidemic, there is an urgent need for diagnostic standards that can be commonly used by pediatricians and hepatologists. To this end, we performed a PubMed search of the adult and pediatric literature on NAFLD diagnosis through May 2011 using Topics and/or relevant Authors as search words. According to the present literature, NAFLD is suspected based on the association of fatty liver combined with risk factors (mainly obesity), after the exclusion of other causes of liver disease. The reference but imperfect standard for confirming NAFLD is liver histology. The following surrogate markers are presently used to estimate degree of steatosis and liver fibrosis and risk of progression to end-stage liver disease: imaging by ultrasonography or magnetic resonance imaging, liver function tests, and serum markers of liver fibrosis.NAFLD should be suspected in all of the overweight or obese children and adolescents older than 3 years with increased waist circumference especially if there is a NAFLD history in relatives. The typical presentation, however, is in children ages 10 years and older. The first diagnostic step in these children should be abdominal ultrasound and liver function tests, followed by exclusion of other liver diseases. Overweight/obese children with normal ultrasonographic imaging and normal liver function tests should still be monitored due to the poor sensitivity of these tests at a single assessment.Indications for liver biopsy include the following: to rule out other treatable diseases, in cases of clinically suspected advanced liver disease, before pharmacological/surgical treatment, and as part of a structured intervention protocol or clinical research trial.
Comment in
-
[Fatty liver disease in children: a growing health problem].Acta Gastroenterol Latinoam. 2012 Sep;42(3):250-8. Acta Gastroenterol Latinoam. 2012. PMID: 23214357 Spanish. No abstract available.
Similar articles
-
Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.Semin Liver Dis. 2007 Aug;27(3):312-8. doi: 10.1055/s-2007-985075. Semin Liver Dis. 2007. PMID: 17682977 Review.
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
Nonalcoholic fatty liver disease: a challenge for pediatricians.Int J Obes (Lond). 2010 Oct;34(10):1451-67. doi: 10.1038/ijo.2010.185. Epub 2010 Sep 14. Int J Obes (Lond). 2010. PMID: 20838401 Review.
-
Advances in pediatric nonalcoholic fatty liver disease.Pediatr Clin North Am. 2011 Dec;58(6):1375-92, x. doi: 10.1016/j.pcl.2011.09.005. Epub 2011 Oct 14. Pediatr Clin North Am. 2011. PMID: 22093857 Review.
-
Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents?Nutr Hosp. 2010 Sep-Oct;25(5):712-7. Nutr Hosp. 2010. PMID: 21336425 Review.
Cited by
-
Non-alcoholic fatty liver disease and lipotoxicity.Clin Exp Hepatol. 2021 Mar;7(1):1-6. doi: 10.5114/ceh.2021.104441. Epub 2021 Mar 25. Clin Exp Hepatol. 2021. PMID: 34027109 Free PMC article. Review.
-
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets.BMC Pediatr. 2013 Mar 25;13:40. doi: 10.1186/1471-2431-13-40. BMC Pediatr. 2013. PMID: 23530957 Free PMC article. Review.
-
Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway.PLoS One. 2016 Jun 16;11(6):e0157246. doi: 10.1371/journal.pone.0157246. eCollection 2016. PLoS One. 2016. PMID: 27310371 Free PMC article. Clinical Trial.
-
The Potential Role of Iron and Copper in Pediatric Obesity and Nonalcoholic Fatty Liver Disease.Biomed Res Int. 2015;2015:287401. doi: 10.1155/2015/287401. Epub 2015 Jul 26. Biomed Res Int. 2015. PMID: 26273604 Free PMC article. Review.
-
The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity.Metabolites. 2022 Dec 5;12(12):1221. doi: 10.3390/metabo12121221. Metabolites. 2022. PMID: 36557260 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical